Mechanisms of action and targets for actual and future antiplatelet drugs.
Platelets are key players in arterial thrombosis and have become important targets in the primary and secondary prevention of atherothrombosis. Antiplatelet drugs are primarily directed against platelets and inhibit platelet activation by a number of different mechanisms. They are used for the prevention and treatment of thrombotic processes, especially in the arterial vascular system. Antiplatelet drugs in clinical use and experimental drugs are discussed.
Freson
Kathleen
K
Center for Molecular and Vascular Biology, University of Leuven, Leuven, Belgium. Kathleen.freson@med.kuleuven.ac.be
Thys
Chantal
C
Wittevrongel
Christine
C
Van Geet
Chris
C
D001241:Aspirin / Q000494:pharmacology; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology*; D015195:Drug Design; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000737:chemistry / Q000494:pharmacology*; D040201:Platelet Membrane Glycoprotein IIb / Q000187:drug effects*; D058914:Purinergic Antagonists; D011725:Pyridines / Q000494:pharmacology
D016861:Cyclooxygenase Inhibitors; D010975:Platelet Aggregation Inhibitors; D040201:Platelet Membrane Glycoprotein IIb; D058914:Purinergic Antagonists; D011725:Pyridines; C446540:thienopyridine; D001241:Aspirin